Navigation Links
Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
Date:11/20/2013

>.

"During implantation in this study, the Humacyte investigational vessel behaved very much like a native vein.  Anastomotic hemostasis was achieved almost immediately. Insertion of needles to perform hemodialysis was easy and as reported by our nephrologists, provides very good adequacy of hemodialysis," said Investigator Marek Ilzecki, M.D., Ph.D., senior resident, Department of Vascular Surgery and Angiology, Medical University of Lublin, Poland.

U.S. Clinical Trial Started in May, 2013

A multi-center U.S. clinical trial began in May, 2013 under a U.S. Investigational New Drug (IND) application. The U.S. trial will involve up to 20 patients across three sites to assess safety and performance of the innovative, investigational bioengineered blood vessels to provide vascular access for hemodialysis in ESRD patients.

About the Investigational Bioengineered Blood Vessels

The Humacyte investigational bioengineered blood vessels are manufactured in a novel bioreactor system. The investigational bioengineered vessels go through a process of decellularization, which is designed to render them potentially non-immunogenic and implantable into any patient. These investigational bioengineered vessels are designed to be stored off-the-shelf for up to 12 months under standard refrigerated conditions, including, if successfully developed and approved,  on-site in hospitals. Subject to receipt of regulatory approval, these properties could make the investigational bioengineered vessels readily available to surgeons and patients, and could eliminate the wait for vessel production or shipping. Data from studies of the investigational bioengineered vessels in large animal models reflect resistance to thickening for up to one year, and the early human studies that are now underway will provide safety and performance data in patients to suppo
'/>"/>

SOURCE Humacyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
3. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
4. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
5. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
9. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
10. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
11. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... SAN DIEGO, Aug. 1, 2014 Arena ... provided a corporate update and reported financial results ... "We have continued to see ... including a 43% quarter-over-quarter increase in estimated total ... the 10,000 mark," said Jack Lief, Arena,s President ...
(Date:7/31/2014)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) ... Chief Business Officer and Executive Vice President. Mr. Singh died ... "Sorrento is deeply saddened and shocked by the ... go to Amar,s family and friends," said Henry Ji ... Mr. Singh joined Sorrento in January 2014 from Synta ...
(Date:7/31/2014)... July 31, 2014 Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® Insulin Pump, today reported its financial results ... In comparing the second quarter of 2014 to the same ... $10.3 million from $5.5 million , t:slim Pump shipments ... In comparing six months ended June 30, 2014 to ...
Breaking Medicine Technology:Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11Sorrento Announces the Unexpected Death of its Chief Business Officer 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6
(Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ( http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly ... use of power morcellators in gynecological surgeries, Bernstein Liebhard ... decision to withdraw a number of power morcellators marketed ... to a report from The New York Times, some ...
(Date:8/1/2014)... and the benefits of a cancer diagnosis may improve ... a study conducted by a researcher at the University ... an expressive writing intervention is the writing instruction. Otherwise, ... events. Writing a journal can be therapeutic, but oftentimes ... it,s effective or not," said Qian Lu, assistant professor ...
(Date:8/1/2014)... DELRAY BEACH, FL (PRWEB) August 01, 2014 ... hosted the 2014 California NextGen User Symposium in San ... event was held at the JW Marriott Union Square ... to help practices get up to speed with ACA ... said earlier this month. The symposium provides attendees guidance ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
(Date:8/1/2014)... (BRONX, NY) Scientists at Albert Einstein ... that bacteria that aid in digestion help keep the ... journal Immunity , could yield new therapies for ... other disorders. , The research involved the intestinal microbiome, ... these microorganisms in promoting or preventing disease is a ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
... Study found higher levels of staph, E. coli in ... News) -- Could common bacterial infections cause some cases of sudden ... of a study in this week,s issue of The Lancet ... levels of Staphylococcus aureus and Escherichia coli ...
... 29 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... joined the company as Vice President, International ... the development and,execution of clinical and regulatory ... candidates. Dr. Clarke was most recently,Vice President, ...
... MATK ) announced today that it will be ... Medical Technology,Conference in New York. The conference is being ... Palace Hotel. Peter L. Buzy, CFO is scheduled to ... Time., A live audio webcast of Martek,s presentation ...
... Ltd.,(Nasdaq: EMITF ) ("EI" or the "Company") today ... Loss for the first quarter of 2008 amounted to ... of NIS 27.3 million,(approximately US$ 7.7 million) is attributable ... NIS 23.8 million (approximately US$ 6.7,million) is attributable to ...
... the continued presence of a doula an experienced non-medical ... beneficial effects for middle- and upper-class women in childbirth, even ... with them, according to a new study in the journal ... of 420 pregnant women in their third trimester were randomized ...
... A critical enzyme used to prepare a powerful ... better target the cells the natural product attacks, according ... the Journal of Biological Chemistry. , Building on their ... Boston College and the University of Wisconsin, Madison discovered ...
Cached Medicine News:Health News:Bacterial Infection May Boost SIDS Risk 2Health News:Bacterial Infection May Boost SIDS Risk 3Health News:Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations 2Health News:Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 2Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 5Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 6Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 7Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 8Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 9Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 10Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 11Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 12Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 13Health News:Enzyme may hold key to improved targeting of cancer-fighting drugs 2
... bring a new standard in the field of ... Labs. Made of medical grade silicone, these durable ... a high level of flexibility while maintaining correct ... available in varying stiffnesses. Lengths are determined by ...
... primary objective of the BioPro Toe implant ... will relieve pain and restore motion while ... undisturbed. The procedure used to implant the ... resection. , ,The design for the great ...
Ad-Techs Spinal Electrodes are intended for intraoperative monitoring of Evoked Potentials (EPs) of the descending pathway during spinal surgery. They are offered with 2 or 3 platinum contacts....
... of Ad-Techs products, our Sphenoidal Electrodes are manufactured ... available in stainless steel or platinum and feature ... (70 mm) long, 21 gauge (0.83 mm) introducing ... as kits or sets. You can also choose ...
Medicine Products: